Free tool
FAERS Monitor: Yutrepia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213005 or its brand name (Yutrepia, Treprostinil Sodium). Reports on generic versions are filed under their own applications.
Reports
10,115
Serious
6,803
67% of reports
Hospitalization
4,556
Death reported
1,369
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea2,186
- headache2,024
- cough1,793
- diarrhoea1,558
- nausea1,323
- dizziness1,227
- fatigue1,199
- hypotension812
- death744
- oxygen saturation decreased692
- vomiting646
- malaise559
- dyspnoea exertional539
- pain in extremity525
- pneumonia504
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 13 |
| 2011 | 22 |
| 2012 | 40 |
| 2013 | 42 |
| 2014 | 71 |
| 2015 | 146 |
| 2016 | 90 |
| 2017 | 103 |
| 2018 | 101 |
| 2019 | 456 |
| 2020 | 481 |
| 2021 | 623 |
| 2022 | 865 |
| 2023 | 1,150 |
| 2024 | 1,046 |
| 2025 | 1,754 |
| 2026 | 3,097 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,044 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyspnoea exertionalSignal | 539 | 30.2 | 27.8 | 14,984 |
| oxygen saturation decreasedSignal | 692 | 25.9 | 24.1 | 16,388 |
| coughSignal | 1,793 | 13.4 | 12.8 | 20,659 |
| hypotensionSignal | 812 | 8.4 | 7.9 | 5,354 |
| dyspnoeaSignal | 2,186 | 8.1 | 7.8 | 13,825 |
| headacheSignal | 2,024 | 6.7 | 6.5 | 10,142 |
| dizzinessSignal | 1,227 | 5.1 | 4.9 | 4,159 |
| diarrhoeaSignal | 1,558 | 5.0 | 4.8 | 5,171 |
| pain in extremitySignal | 525 | 3.7 | 3.4 | 1,049 |
| nauseaSignal | 1,323 | 3.5 | 3.3 | 2,423 |
| pneumoniaSignal | 504 | 3.2 | 3.0 | 789 |
| fatigueSignal | 1,199 | 3.2 | 3.0 | 1,884 |
| vomitingSignal | 646 | 2.9 | 2.7 | 796 |
| malaiseSignal | 559 | 2.7 | 2.4 | 585 |
| death | 744 | 1.8 | 1.7 | 273 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.